These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1296 related articles for article (PubMed ID: 24240112)

  • 1. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM
    Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
    D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
    Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
    Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
    Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
    Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM
    Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
    Hyman DM; Zhou Q; Arnold AG; Grisham RN; Iasonos A; Kauff ND; Spriggs D
    Gynecol Oncol; 2011 Nov; 123(2):196-9. PubMed ID: 21855118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
    Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
    J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    Li W; Shao D; Li L; Wu M; Ma S; Tan X; Zhong S; Guo F; Wang Z; Ye M
    J Ovarian Res; 2019 Aug; 12(1):80. PubMed ID: 31472684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited Mutations in Women With Ovarian Carcinoma.
    Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
    JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
    Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.